BioSpace News Archive

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has approved Dupixent® for the treatment of adult patients with prurigo nodularis.

The U.S. Food and Drug Administration has approved Dupixent® for the treatment of adult patients with prurigo nodularis.

Children’s Cancer Research Fund recently awarded these eight promising scientists the Emerging Scientist Award, each worth $100,000, to pursue their research in the childhood cancer field:

Scientific Industries, Inc. announced it will file a Form 10K for its financial results for the year ended June 30, 2022, and issue a press release reporting its fiscal year 2022 before the market open on Thursday, September 29, 2022.

Eureka Therapeutics, Inc. announced the publication of a study in the New England Journal of Medicine entitled “GPRC5D-Targeted CAR T Cells for Myeloma.” The study was led by Dr. Eric Smith of the Dana-Farber Cancer Institute, Dr. Renier Brentjens of the Roswell Park Comprehensive Cancer Center, and Dr. Sham Mailankody of the Memorial Sloan Kettering Cancer Center.

AVITA Medical, Inc. announced the appointment of James Corbett as Chief Executive Officer, effective immediately.

Sirona Biochem Corp. announces the release of a corporate update which highlights the company’s recent team meeting in France, the current pipeline, and the latest deal structure.

Simcere Pharmaceutical Group, an innovation and R&D-driven pharmaceutical company, and Almirall S.A., a global biopharmaceutical company focused on skin health; announced that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein autoimmune drug candidate, SIM0278.